Clinical and Electrophysiological Heterogeneity in Adult Charcot-Marie-Tooth Disease
Clinical and Electrophysiological Heterogeneity in Adult Charcot-Marie-Tooth Disease: An Observational Study of the Relationships Between CMTES-v2, Nerve Conduction Parameters, and Functional Capacity
CMT-PROFILE is a single-center, cross-sectional observational study involving adults with Charcot-Marie-Tooth disease (CMT). The study will investigate the association between clinical disease severity, measured using the CMT Examination Score version 2 (CMTES-v2), and motor electrophysiological parameters, including compound muscle action potential (CMAP) amplitudes and motor nerve conduction velocities. Secondary objectives include characterizing clinical-electrophysiological concordance, comparing functional capacity, muscle strength and mobility across concordance groups, and exploring demographic, clinical, biological and genetic factors associated with variability in disease expression. Approximately 250 patients are planned for inclusion. All assessments will be performed at a single reference time point (M0), with no longitudinal follow-up.
研究概览
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Abderhmane Slioui
- 电话号码:+33 0492038953
- 邮箱:slioui.a@chu-nice.fr
研究联系人备份
- 姓名:Angela Puma
- 电话号码:+33 0492035435
- 邮箱:puma.ar@chu-nice.fr
学习地点
-
-
Alpes Maritimes
-
Nice、Alpes Maritimes、法国、06000
- CHU de Nice
-
接触:
- Abderhmane Slioui
- 电话号码:+33 0492038953
- 邮箱:slioui.a@chu-nice.fr
-
接触:
- Angela de Nice
- 电话号码:+33 0492035435
- 邮箱:puma.ar@chu-nice.fr
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Adults with Charcot-Marie-Tooth disease evaluated at the Peripheral Neuromuscular Rare Disease Reference Center of Nice University Hospital. The study aims to characterize the relationships between clinical disease severity, assessed using the CMTES-v2, motor electrophysiological parameters, and functional capacity. Participants will undergo a single reference assessment (M0), with no subsequent follow-up. The planned sample size is approximately 250 participants, subject to confirmation against the approved protocol.
描述
Inclusion Criteria:
- Adults aged 18 years or older.
- Diagnosis of peripheral sensory polyneuropathy.
- Classification as length-dependent (LDN) or non-length-dependent (NLDN) based on clinical and electrophysiological findings.
- Available nerve conduction study including sural and radial sensory nerve amplitudes allowing calculation of the SRAR.
- Evaluated at the Peripheral Neuromuscular Rare Disease Reference Center, Nice University Hospital, between January 2013 and July 2026.
Exclusion Criteria:
- Missing or incomplete clinical or electrophysiological data preventing SRAR calculation.
- Unclassifiable neuropathy phenotype.
- Technical factors affecting the reliability of nerve conduction studies.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:CROSS_SECTIONAL
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Adults with Charcot-Marie-Tooth Disease
|
This observational, cross-sectional study evaluates clinical severity, electrophysiological parameters, and functional capacity in adults with Charcot-Marie-Tooth disease (CMT). Data collected at a single reference time point (M0) include the CMT Examination Score version 2 (CMTES-v2), nerve conduction study parameters, including compound muscle action potential (CMAP) amplitudes and motor nerve conduction velocities, and available functional and clinical measures. Additional variables may include muscle strength, mobility, pain, patient-perceived disease severity, occupational impact, and demographic, clinical, and genetic characteristics, as specified in the study protocol. No study-specific treatment or intervention is administered. There is no longitudinal follow-up |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Association Between CMTES-v2 and Motor Electrophysiological Parameters
大体时间:At day 0 (single assessment; no follow-up).
|
To assess the association between the CMTES-v2 total score and prespecified motor electrophysiological parameters, including distal CMAP amplitudes and motor nerve conduction velocities, using correlation analyses as specified in the statistical analysis plan. |
At day 0 (single assessment; no follow-up).
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Clinical-Electrophysiological Concordance and Discordance Classification
大体时间:At Day 0 (single assessment; no follow-up).
|
disease severity and electrophysiological impairment, using standardized residuals derived from the difference between observed CMTES-v2 scores and scores predicted from motor electrophysiological parameters, divided by the residual standard deviation. Patients will be classified into three mutually exclusive categories: concordant (standardized residual between -1.96 and +1.96), greater clinical severity than predicted (standardized residual above +1.96), or lower clinical severity than predicted (standardized residual below -1.96). Results will be expressed as the number and percentage of patients in each category. |
At Day 0 (single assessment; no follow-up).
|
|
Age at Assessment Across Clinical-Electrophysiological Concordance Groups
大体时间:At Day 0 (single assessment; no follow-up)
|
To investigate whether age at clinical assessment differs according to the degree of clinical-electrophysiological concordance, age will be recorded in years and compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up)
|
|
Age at Symptom Onset Across Clinical-Electrophysiological Concordance Groups
大体时间:At Day 0 (single assessment; no follow-up)
|
To investigate whether age at clinical assessment differs according to the degree of clinical-electrophysiological concordance, age will be recorded in years and compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up)
|
|
Disease Duration Across Clinical-Electrophysiological Concordance Groups
大体时间:At Day 0 (single assessment; no follow-up)
|
To evaluate the relationship between disease duration and clinical-electrophysiological concordance, disease duration will be calculated as the interval, expressed in years, between the reported onset of symptoms and the reference clinical assessment. Disease duration will be compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up)
|
|
Genetic Subtype Distribution Across Clinical-Electrophysiological Concordance Groups
大体时间:At Day 0 (single assessment; no follow-up)
|
To investigate whether the distribution of genetically confirmed Charcot-Marie-Tooth disease subtypes differs according to clinical-electrophysiological concordance, genetic subtypes documented in the medical records will be categorized and compared across the three predefined concordance groups. Results will be reported as the number and percentage of patients within each genetic subtype among those with available genetic data. |
At Day 0 (single assessment; no follow-up)
|
|
Functional Performance Across Clinical-Electrophysiological Concordance Groups (CMT-FOM)
大体时间:At Day 0 (single assessment; no follow-up).
|
To evaluate whether functional performance differs according to clinical-electrophysiological concordance, functional capacity will be quantified using the total score of the Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM). Scores will be compared across the three predefined concordance groups among patients with available assessments. |
At Day 0 (single assessment; no follow-up).
|
|
Muscle Strength Across Clinical-Electrophysiological Concordance Groups (MRC Scale)
大体时间:At Day 0 (single assessment; no follow-up)
|
To assess differences in muscle strength according to clinical-electrophysiological concordance, muscle strength will be evaluated using the Medical Research Council (MRC) grading scale, ranging from 0 (no visible or palpable muscle contraction) to 5 (normal muscle strength). Recorded muscle strength grades will be compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up)
|
|
Right Handgrip Strength Across Clinical-Electrophysiological Concordance Groups
大体时间:At Day 0 (single assessment; no follow-up)
|
To assess differences in right handgrip strength according to clinical-electrophysiological concordance, right handgrip strength will be measured by dynamometry, with the highest value obtained from three trials retained for analysis. Measurements will be compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up)
|
|
Left Handgrip Strength Across Clinical-Electrophysiological Concordance Groups
大体时间:At Day 0 (single assessment; no follow-up).
|
To assess differences in left handgrip strength according to clinical-electrophysiological concordance, left handgrip strength will be measured by dynamometry, with the highest value obtained from three trials retained for analysis. Measurements will be compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up).
|
|
Functional Mobility Across Clinical-Electrophysiological Concordance Groups (Timed Up and Go)
大体时间:At Day 0 (single assessment; no follow-up)
|
To investigate differences in functional mobility according to clinical-electrophysiological concordance, mobility will be assessed using the Timed Up and Go (TUG) test, measuring the time required to rise from a chair, walk three meters, turn, return to the chair and sit down. Completion time will be recorded in seconds and compared across the three predefined concordance groups. Inability to complete the test safely will be recorded as a non-feasible assessment rather than assigned an arbitrary completion time. |
At Day 0 (single assessment; no follow-up)
|
|
Pain Intensity Across Clinical-Electrophysiological Concordance Groups
大体时间:At Day 0 (single assessment; no follow-up).
|
To investigate whether pain intensity differs according to clinical-electrophysiological concordance, average pain intensity over the preceding seven days will be assessed using an 11-point numerical rating scale, ranging from 0 (no pain) to 10 (worst imaginable pain). Pain scores will be compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up).
|
|
Patient-Perceived Disease Severity Across Clinical-Electrophysiological Concordance Groups
大体时间:At Day 0 (single assessment; no follow-up)
|
To evaluate differences in patient-perceived disease severity according to clinical-electrophysiological concordance, overall disease severity will be self-rated using a five-point ordinal scale ranging from 1 (very mild) to 5 (very severe). Scores will be compared across the three predefined concordance groups. |
At Day 0 (single assessment; no follow-up)
|
|
Work Absenteeism Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
大体时间:At Day 0 (single assessment; no follow-up)
|
To investigate differences in work absenteeism associated with Charcot-Marie-Tooth disease according to clinical-electrophysiological concordance, absenteeism will be assessed using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) and quantified as the percentage of working time missed due to the disease during the preceding seven days, ranging from 0% to 100%. Comparisons will be performed across the three predefined concordance groups among employed participants for whom the measure is applicable. |
At Day 0 (single assessment; no follow-up)
|
|
Work Presenteeism Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
大体时间:At Day 0 (single assessment; no follow-up).
|
To investigate differences in work-related productivity impairment while present at work according to clinical-electrophysiological concordance, presenteeism will be assessed using the WPAI:SHP questionnaire and expressed as the percentage of impairment while working attributable to Charcot-Marie-Tooth disease during the preceding seven days, ranging from 0% to 100%. Results will be compared across the three predefined concordance groups among participants for whom the measure is applicable. |
At Day 0 (single assessment; no follow-up).
|
|
Overall Work Productivity Impairment Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
大体时间:At Day 0 (single assessment; no follow-up).
|
To assess whether overall work productivity impairment differs according to clinical-electrophysiological concordance, overall impairment will be calculated from the absenteeism and presenteeism components of the WPAI:SHP questionnaire and expressed as a percentage ranging from 0% (no impairment) to 100% (complete impairment) over the preceding seven days. Results will be compared across the three predefined concordance groups among participants for whom the measure is applicable |
At Day 0 (single assessment; no follow-up).
|
|
Daily Activity Impairment Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)
大体时间:At Day 0 (single assessment; no follow-up)
|
To assess differences in the impact of Charcot-Marie-Tooth disease on usual daily activities according to clinical-electrophysiological concordance, activity impairment will be quantified using the WPAI:SHP questionnaire and expressed as a percentage ranging from 0% (no impairment) to 100% (complete impairment) over the preceding seven days. Results will be compared across the three predefined concordance groups, irrespective of employment status |
At Day 0 (single assessment; no follow-up)
|
合作者和调查者
调查人员
- 首席研究员:Angela Puma、Centre Hospitalier Universitaire de Nice
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 26Neuro06
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.